Rafael Holdings disclosed that Trappsol Cyclo failed its primary endpoint in a pivotal NPC study despite positive prespecified subgroup results, resulting in a potential delay to the 2026 NDA submission.
Rafael Holdings disclosed that Trappsol Cyclo failed its primary endpoint in a pivotal NPC study despite positive prespecified subgroup results, resulting in a potential delay to the 2026 NDA submission.